| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 205,667 | 241,198 |
| Depreciation and amortization | 3,028 | 2,062 |
| Stock-based compensation expense | 14,182 | 10,793 |
| Impairment of out-license asset and remeasurement of cvr liability, net | 1,646 | - |
| Loss on debt extinguishment | -10,286 | -10,286 |
| Gain on sale transactions, net (note 6) | 338,680 | 339,102 |
| Change in fair value of derivatives | 12,608 | 12,608 |
| Other non-cash adjustments, net | -5,352 | 2,490 |
| Trade receivables, net | -101,895 | -106,161 |
| Inventory | 15,994 | 18,474 |
| Prepaid manufacturing | 952 | -396 |
| Other prepaid, current and non-current assets | -2,405 | 869 |
| Accounts payable | -14,468 | 833 |
| Accrued rebates, fees and reserves | -89,114 | -68,053 |
| Tsa related operating assets and liabilities, net | -12,641 | 10,547 |
| Accrued compensation | -4,959 | -7,329 |
| Accrued and other current and non-current liabilities | -13,636 | -14,911 |
| Net cash (used in) provided by operating activities | -118,797 | -72,458 |
| Purchases of investments in marketable securities | 89,576 | 20,726 |
| Proceeds from maturities of investments in marketable securities | 1,650 | - |
| Net cash received related to the sale transactions (note 6) | -478,681 | -478,681 |
| Milestone payment to junshi biosciences | 12,500 | 12,500 |
| Other investing activities, net | 330 | 303 |
| Net cash provided by investing activities | 377,925 | 445,152 |
| Proceeds from (repayment of) revenue purchase and sale agreement, net of issuance costs | -47,652 | -47,652 |
| Proceeds from purchase under the employee stock purchase plan | 188 | 188 |
| Taxes paid related to net share settlement | 283 | 280 |
| Redemption of 2026 convertible notes, including transaction costs | 233,185 | 233,185 |
| Other financing activities, net | -854 | -859 |
| Net cash used in financing activities | -281,786 | -281,788 |
| Net increase in cash, cash equivalents and restricted cash | -22,658 | 90,906 |
| Cash and cash equivalents at beginning of period | 126,250 | - |
| Cash and cash equivalents at end of period | 103,592 | - |
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)